Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis

Author:

Grace Angeline G1,Mittal Abhenil2,Jain Siddharth3,Tripathy Jaya P4,Satyanarayana Srinath5,Tharyan Prathap6,Kirubakaran Richard7

Affiliation:

1. Sree Balaji Medical College & Hospital; Department of Community Medicine; Works road Chrompet Chennai India 600044

2. All India Institute of Medical Sciences; Department of Internal Medicine; New Delhi India

3. Postgraduate Institute of Medical Education and Research (PGIMER); Clinical Immunology and Rheumatology Unit, Department of Internal Medicine; Chandigarh India 160012

4. International Union Against Tuberculosis and Lung Disease (The Union), South-East Asia Regional Office; Centre for Operational Research; New Delhi India

5. International Union Against Tuberculosis and Lung Disease (The Union), South-East Asia Regional Office; New Delhi India

6. Christian Medical College; Clinical Epidemiology Unit, Prof. BV Moses Centre for Evidence-Informed Healthcare and Health Policy; Carman Block II Floor CMC Campus, Bagayam Vellore Tamil Nadu India 632002

7. Christian Medical College; Cochrane South Asia, Prof. BV Moses Centre for Evidence-Informed Healthcare and Health Policy; Carman Block II Floor CMC Campus, Bagayam Vellore India 632002

Publisher

Wiley

Subject

Pharmacology (medical)

Reference99 articles.

1. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis;Gillespie;New England Journal of Medicine,2014

2. NCT00864383 Controlled comparison of two moxifloxacin containing treatment shortening regimens in pulmonary tuberculosis (REMoxTB) https://clinicaltrials.gov/ct2/show/NCT00864383

3. Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials;Phillips;BMC Medicine,2016

4. A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens;Phillips;BMC Medicine,2017

5. CTRI/2012/10/003060 A study of the efficacy and tolerability of moxifloxacin and gatifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=5124&EncHid=&userName=CTRI/2012/10/003060

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3